Synergistic anti-tumour activity of sorafenib in combination with pegylated resveratrol is mediated by Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways.

Ligang Wang, Hao Wu,Ying Wang, Songcheng Xu,Chen Yang, Tingting Zhang,Yang Liu,Fuwei Wang,Weinan Chen,Jianchun Li,Litao Sun

Heliyon（2023）

引用 0|浏览4

暂无评分

摘要

PEGylated resveratrol combined with sorafenib can achieve synergistic anti-RCC activity, and the mechanism may be related to the inhibition of Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways.

查看译文

关键词

Resveratrol,Sorafenib,Combination,Kidney cancer,Akt/mTOR/p70S6k-4EBP-1,c-Raf7MEK/ERK,Signaling pathway

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要